🚀 VC round data is live in beta, check it out!
Grand Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Grand Pharmaceutical and similar public comparables like Apeloa Pharmaceutical, Vera Therapeutics, Arcus Biosciences, Arcutis Biotherapeutics and more.
Grand Pharmaceutical Overview
About Grand Pharmaceutical
Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.
Founded
1995
HQ
Employees
12.0K
Website
Financials (LTM)
EV
$3B
Grand Pharmaceutical Financials
Grand Pharmaceutical reported last 12-month revenue of $2B and EBITDA of $308M.
In the same LTM period, Grand Pharmaceutical generated $900M in gross profit, $308M in EBITDA, and $175M in net income.
Revenue (LTM)
Grand Pharmaceutical P&L
In the most recent fiscal year, Grand Pharmaceutical reported revenue of $1B and EBITDA of $452M.
Grand Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $900M | XXX | $861M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $308M | XXX | $452M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $175M | XXX | $316M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | — | — | $389M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Grand Pharmaceutical Stock Performance
Grand Pharmaceutical has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Grand Pharmaceutical's stock price is $0.86.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -0.5% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGrand Pharmaceutical Valuation Multiples
Grand Pharmaceutical trades at 2.1x EV/Revenue multiple, and 11.0x EV/EBITDA.
EV / Revenue (LTM)
Grand Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Grand Pharmaceutical has market cap of $3B and EV of $3B.
Equity research analysts estimate Grand Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Grand Pharmaceutical has a P/E ratio of 17.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 12.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | 3.9x | XXX | XXX | XXX |
| P/E | 17.3x | XXX | 9.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 20.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Grand Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Grand Pharmaceutical Margins & Growth Rates
Grand Pharmaceutical's revenue in the last 12 month grew by 12%.
Grand Pharmaceutical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Grand Pharmaceutical's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Grand Pharmaceutical's rule of X is 51% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Grand Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | (36%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 31% | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Grand Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Grand Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Apeloa Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Vera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcus Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcutis Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocelltech Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grand Pharmaceutical M&A Activity
Grand Pharmaceutical acquired XXX companies to date.
Last acquisition by Grand Pharmaceutical was on XXXXXXXX, XXXXX. Grand Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Grand Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGrand Pharmaceutical Investment Activity
Grand Pharmaceutical invested in XXX companies to date.
Grand Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Grand Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Grand Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Grand Pharmaceutical
| When was Grand Pharmaceutical founded? | Grand Pharmaceutical was founded in 1995. |
| Where is Grand Pharmaceutical headquartered? | Grand Pharmaceutical is headquartered in China. |
| How many employees does Grand Pharmaceutical have? | As of today, Grand Pharmaceutical has over 12K employees. |
| Who is the CEO of Grand Pharmaceutical? | Grand Pharmaceutical's CEO is Yan Shao. |
| Is Grand Pharmaceutical publicly listed? | Yes, Grand Pharmaceutical is a public company listed on HKEX. |
| What is the stock symbol of Grand Pharmaceutical? | Grand Pharmaceutical trades under 00512 ticker. |
| When did Grand Pharmaceutical go public? | Grand Pharmaceutical went public in 1995. |
| Who are competitors of Grand Pharmaceutical? | Grand Pharmaceutical main competitors are Apeloa Pharmaceutical, Vera Therapeutics, Arcus Biosciences, Arcutis Biotherapeutics. |
| What is the current market cap of Grand Pharmaceutical? | Grand Pharmaceutical's current market cap is $3B. |
| What is the current revenue of Grand Pharmaceutical? | Grand Pharmaceutical's last 12 months revenue is $2B. |
| What is the current revenue growth of Grand Pharmaceutical? | Grand Pharmaceutical revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Grand Pharmaceutical? | Current revenue multiple of Grand Pharmaceutical is 2.1x. |
| Is Grand Pharmaceutical profitable? | Yes, Grand Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Grand Pharmaceutical? | Grand Pharmaceutical's last 12 months EBITDA is $308M. |
| What is Grand Pharmaceutical's EBITDA margin? | Grand Pharmaceutical's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Grand Pharmaceutical? | Current EBITDA multiple of Grand Pharmaceutical is 11.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.